Research and Markets : See These Comprehensive Strategies And Tactics That Improve Patient Recruitment and Retention In Clinical Studies Today
Research and Markets (researchandmarkets. com/reports/c13595) has announced the addition of Strategies And Tactics That Improve Patient Recruitment and Retention in Clinical Studies to their offering.
(PRWEB) March 9, 2005
Patient recruitment and retention currently represents a critical bottleneck in clinical research and drug development. For example, in some cases, (e. g. breast cancer in the USA) the 'supply' of patients may be inadequate to fully assess all the drugs currently in the pipeline. Furthermore, clinical studies account for around half of the billion-dollar cost of drug development. Clinical studies are also becoming larger, longer and more complex. Therefore, there is a pressing need to reduce costs and get drugs to market more rapidly. But many clinical studies are both ineffective and inefficient. Some 70% of sites miss their recruitment target, for example. The report covers the 'scientific' aspects that contribute to the bottleneck, including enrolling of an appropriate race, age and pharmacogenomic profile to represent patients likely to receive the drug in clinical practice and access to naive patient populations.
Research and Markets (http://www. researchandmarkets. com/reports/c13595 (http://www. researchandmarkets. com/reports/c13595)) has announced the addition of Strategies And Tactics That Improve Patient Recruitment and Retention in Clinical Studies to their offering.
This Report considers strategies and tactics that enhance clinical studies' efficacy and efficient by ensuring that appropriate patients enroll in clinical studies in the most cost-effective manner. The Report begins with an analysis of barriers that hinder effective patient recruitment and then considers some solutions. In addition, the Report focuses on the role played by IT, advertising and accessing different patient populations, such as volunteers from Central and Eastern Europe as well as South America.
Key Reasons to Buy this Report.
Learn why sponsors need to improve patient recruitment and retention through an overview of the numerous factors that drive the increasing length, size, and complexity of clinical studies. Identify patient recruitment barriers through an extensive review of the factors that hinder recruitment and retention (eg. complicated protocols, over-rigorous inclusion and exclusion criteria, etc.).
Identify solutions that work - illustrated by extensive review and numerous case histories of strategies and tactics that have been shown to improve recruitment and retention. Obtain a thorough understanding of the circumstances in which advertising can still offer a highly cost-effective means to recruit patients and improve the quality and quantity of patients enrolled.
Get an in-depth look at the technological and other innovations introduced by CROs and IT companies to improve dramatically the conduct and management of clinical trials generally and recruitment and retention more specifically. Understand why a growing number of clinical trials are performed in emerging countries, including cost benefits, large populations, pharmacogenetic profiling, etc., as well as the issues that sponsors to consider. Gain reliable and thought-provoking insights into key factors influencing patient recruitment through in-depth interviews with 11 world authorities. Look inside 21 companies offering skills and services in the patient retention and recruitment area including their strategic alliances, products and pipelines, financial status, and more.
Market Opportunities
Move studies to low cost countries could save between US$10,000 and US$15,000 per enrolled patient. Effective and efficient patient recruitment can help drugs reach the market more quickly. Every extra day that a drug remains in clinical studies costs the sponsor at least US$ 600 000 in lost sales, for example. For a potential blockbuster, the daily lost revenue could reach US$ 8 million. Educate the public to help overcome bad press and pervasive historical influence (for example. The Tuskegee study) that undermines the sector's credibility and contributes to poor health outcomes as well as poor recruitment and retention. Develop child-friendly protocols that allow the sponsor to collect high quality data as regulatory authorities increasingly focus on this population.
The contents of this report are as follows:
1 Executive Summary
2 Introduction
Context
Clinical Trials: Ineffective and Inefficient?
Patient Recruitment: The Key to a Successful Study
Sources of Information
3 Factors Driving the Increasing Length, Size and Complexity of Clinical Studies
Context
Increasing R&D costs
Increasing Size of Clinical Studies
The Impact of Pharmacogenomics
Orphan Drugs Enter the Pharmaceutical Mainstream
Clinical Trial Transparency
The Ethics of Clinical Trials
GCP and the ICH
4 Barriers to Patient Recruitment
The Move Away From The Traditional Clinical Trial Participant
Poor Protocol Equals Poor Recruitment
Modeling Protocols
Investigator-Related Issues
Patient-Related Issues
Recruitment and Retention in Elderly Patients
Recruitment Issues in Ethnic Minorities
Pediatric Clinical Studies
5 Advertising: Tradition Survives in the IT Age
Context
Innovative Approaches to Advertising
Augmenting Advertising with Telephone Screening
6 Patient Recruitment in the New Media Age
Context
An Integrated Approach
Internet Recruitment
Virtual Study Sites
Electronic Informed Consent and Patient Education
New Media versus Traditional Approaches: "Horses for Courses"?
7 New Geographical Areas and Patient Recruitment Overview
Context
An Expanding Market
Large Populations
Cost Benefits
Issues to Consider
8 Estimating the Resource Implications of Improving Patient Recruitment and Retention
Context
Moving Studies to Low Cost Countries
Estimating the Opportunity Costs
Multimedia Presentations Cut Costs: A Case Study
9 Ask the Expert
Joe Avellone, CEO, Veritas Medicine, Inc.
Ashok Bhat, Commercial Operations Director, Phase Forward
Alan Boyce, Vice President, Europe, Kendle
Maria Fernandez Freire, Director, Thywill LatAm Solutions
Richard Gliklich, MD; CEO, Outcome
Janet Jones, Director, Global Feasibility and Patient Access, Kendle
Faiz Kermani, Marketing Executive, Chiltern International
John D McAnulty, Senior Vice President & Partner, Fleishman-Hillard Clinical Trials Division
Larry Meinert, Vice President, Medical and Scientific Affairs, Late Stage Development Services, Covance Inc.
Brian Sanderson, CEO and Medical Director, DDS Medicines Research Limited
Dave Zuckerman, President, Customized Improvement Strategies LLC
10 Company Profiles
11 Towards Effective and Efficient Recruitment and Retention
Elements in Effective and Efficient Recruitment and Retention
The Importance of Contingency Plans
For more information visit http://www. researchandmarkets. com/reports/c13595 (http://www. researchandmarkets. com/reports/c13595)
Laura Wood
Senior Manager
Research and Markets
Press@researchandmarkets. com
Fax: +353 1 4100 980
###
